F-STAR THERAPEUTICS INC (FSTX) Stock Price, Forecast & Analysis
USA - NASDAQ:FSTX - US30315R1077 - Common Stock
FSTX Key Statistics, Chart & Performance
The current stock price of FSTX is 7.12 USD. In the past month the price increased by 58.22%. In the past year, price increased by 138.13%.
FSTX Latest News, Press Relases and Analysis
FSTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About FSTX
Company Profile
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. The firm's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. The company is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.
Company Info
F-STAR THERAPEUTICS INC
Eddeva B920, Babraham Research Campus
CAMBRIDGE MASSACHUSETTS CB22 3AT GB
CEO: Eliot Forster
Employees: 84
Phone: 441223497400.0
F-STAR THERAPEUTICS INC / FSTX FAQ
What does FSTX do?
F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. The firm's FS118 is the lead product candidate, which is in Phase II trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. The company is also developing FS222, FS120 and SB 11285 in Phase I clinical trials in patients with advanced cancers. FS222 is focused on patients with tumors that express low levels of PD-L1 and is a tetravalent, bispecific natural antibody (mAb2) bispecific antibody that is designed to target both the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. FS120 is focused to improve checkpoint inhibitor and chemotherapy outcomes and is a mAb2 bispecific antibody that is designed to bind to and stimulate OX40 and CD137. Its product candidate SB 11285 is focused on improving checkpoint inhibition outcomes as an immunotherapeutic compound for the treatment of selected cancers.
What is the current price of FSTX stock?
The current stock price of FSTX is 7.12 USD.
Does F-STAR THERAPEUTICS INC pay dividends?
FSTX does not pay a dividend.
How is the ChartMill rating for F-STAR THERAPEUTICS INC?
FSTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of F-STAR THERAPEUTICS INC (FSTX)?
F-STAR THERAPEUTICS INC (FSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.81).
Can you provide the market cap for F-STAR THERAPEUTICS INC?
F-STAR THERAPEUTICS INC (FSTX) has a market capitalization of 156.51M USD. This makes FSTX a Micro Cap stock.
FSTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FSTX. When comparing the yearly performance of all stocks, FSTX is one of the better performing stocks in the market, outperforming 98.78% of all stocks.
FSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FSTX. The financial health of FSTX is average, but there are quite some concerns on its profitability.
FSTX Financial Highlights
Over the last trailing twelve months FSTX reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 60.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.15 |
FSTX Forecast & Estimates
9 analysts have analysed FSTX and the average price target is 7.14 USD. This implies a price increase of 0.28% is expected in the next year compared to the current price of 7.12.
For the next year, analysts expect an EPS growth of -39.55% and a revenue growth -70.62% for FSTX